White House trade adviser Peter Navarro has promoted the “astonishing” results of an observational study that found hydroxychloroquine was associated with lower mortality for patients hospitalized for COVID-19. But the study has limitations, and multiple randomized controlled trials have found the drug is not beneficial to hospitalized patients.
Stories by Jessica McDonald
SciCheck Editor
Trump’s False Claim on Coronavirus Harm
Trump Falsely Says COVID-19 Surge ‘Only’ Due to Testing, Misleads on Deaths
Azar, Trump Mislead on FDA’s Hydroxychloroquine Decision
At the White House, the Health and Human Services secretary left the misleading impression that the FDA’s decision to revoke its emergency use authorization of hydroxychloroquine and chloroquine for COVID-19 “removes a potential barrier” and makes it easier to access the drugs. The FDA’s action does the opposite.
Ahead of Trump Rally, Republicans Spin COVID-19 Metrics
Unpacking WHO’s Asymptomatic COVID-19 Transmission Comments
At a June 8 press conference, a World Health Organization scientist confusingly suggested that asymptomatic transmission of the coronavirus is “very rare” — a statement that many scientists found problematic, and which some politicians and those on social media seized upon as evidence that certain public health measures were not necessary.